**Topic: Single Cells, Big Data: How one cell can tell a thousand stories; Description: Explore the revolution of single-cell RNA-seq and what it reveals about cell identity and disease**

1. **Introduction** 

The advent of high-throughput sequencing technologies has revolutionized molecular biology, fundamentally transforming our ability to study the dynamic landscape of an organism's genetic activity. At the heart of this transformation is RNA sequencing (RNA-seq), a powerful genomic approach developed around 2008 (1–4) that allows for the detection and quantitative analysis of all RNA molecules (the transcriptome) within a biological sample. Unlike previous methods such as microarrays or Sanger sequencing, RNA-seq offers unprecedented precision and breadth, enabling the discovery of novel transcripts, alternative splicing patterns, and a comprehensive view of gene expression dynamics that was previously impossible.

Early RNA-seq studies primarily relied on bulk tissue analysis, which involved analyzing RNA extracted from thousands or millions of cells pooled together. While these studies provided a wealth of information about average gene expression within a given tissue or condition, they masked critical biological variations existing between individual cells. This "averaging bias" obscured the subtle but biologically significant differences that dictate cell fate, function, and response to stimuli, particularly in complex systems like the brain, immune system, or developing embryos.

The critical limitation of bulk sequencing led to the development and popularization of single-cell RNA sequencing (scRNA-seq). The importance of studying cells at this individual level is immense:

Uncovering Heterogeneity: It allows researchers to resolve cellular heterogeneity and identify rare cell populations, such as specific immune cell subtypes or malignant tumor cells, that would otherwise remain undetected in a pooled sample.

Tracing Cell Fates: scRNA-seq is instrumental in tracing cell lineage and developmental trajectories, providing a high-resolution map of how cells differentiate and develop over time.

Understanding Disease and Environment: By examining how individual cells interact with their microenvironment or respond to external signals (like drug treatments or infections), scRNA-seq offers insights into disease progression, drug resistance, and the mechanisms underlying cell-to-cell communication.

In essence, RNA-seq transformed molecular biology by providing a high-resolution, quantitative view of the transcriptome, and scRNA-seq further refined this by enabling the investigation of the fundamental unit of biology—the individual cell. This shift from population-averaged data to single-cell resolution continues to drive discovery and innovation across biomedical research, from building comprehensive cell atlases to advancing personalized medicine strategies.



1. **Bulk RNA Sequencing**

Bulk RNA sequencing (bulk RNA-seq) is a widely used transcriptomic technique that measures the average gene expression across a mixed population of cells derived from a tissue or cell sample. It defines the transcriptome profile by quantifying RNA molecules extracted from the entire sample without discriminating between different cell types within that population[6]. A review by Hegenbarth et al. (2022) discusses how bulk RNA-seq captures averaged gene expression profiles from tissue samples, covering gene expression changes in cardiac tissues but noting that it masks cellular heterogeneity intrinsic to complex tissues [5]. This means that since RNA is isolated from a heterogeneous mixture of cells, the resulting data reflect an aggregate signal representing the dominant cell types and states, masking individual cell variability. This averaging approach is suitable for investigating overall molecular changes and gene expression patterns within tissues or complex cell populations. Therefore, this approach is used to identify different sample conditions [6].

The traditional bulk RNA-seq workflow as described by Wang et al. (2020) for clinical oncology includes covering sample harvesting, RNA isolation, library construction (poly-A selection or rRNA depletion), sequencing on Illumina platforms, followed by computational alignment and gene expression quantification. This study also emphasized quality control metrics such as RNA integrity number (RIN) for high-quality data [6].

Wang et al. (2020) applied bulk RNA sequencing to myeloproliferative neoplasm patient samples and healthy controls. They identified significant transcriptional alterations in immune response genes and mutation-associated expression changes, enabling discovery of disease-related expression profiles that differentiate patient from control samples, with clear clinical implications for prognosis and therapy [5 , 6]. Barretto et al. (2025) used bulk RNA sequencing on 53 different neuron types from the *Caenorhabditis elegans* nervous system. They generated transcriptome profiles that offered high sensitivity and specificity for neuron-type-specific gene expression, including non-polyadenylated transcripts. This dataset provided detailed expression patterns at the neuronal population level and complemented existing single-cell data by detecting lowly expressed genes missed by scRNA-seq [7]. Li et al. (2021) review demonstrates bulk RNA-seq in cancer biology, focusing on gene expression differences between tumor and non-tumor tissue. They identified differentially expressed genes involved in tumorigenesis pathways, signaling processes, and immune escape mechanisms, highlighting molecular drivers of cancer progression uncovered by bulk transcriptome profiling [8]. The FoundationOne Heme RNA-seq panel, described by Li et al. (2021), uses bulk RNA sequencing to detect gene fusions, mutations, and expression signatures used clinically as biomarkers for cancer diagnosis, prognosis, and therapy selection. The panel has widespread adoption in clinical labs, demonstrating bulk RNA-seq utility in biomarker-driven precision oncology [8]. The *C. elegans* neuron bulk RNA-seq dataset by Barretto et al. (2025) represents a foundational transcriptomic resource detailing neuronal gene expression in an important model organism. It enables advanced research linking gene expression to neuron function, structure, and connectivity, providing a rich resource for neuroscience and developmental biology communities.

The improvement in bulk rna sequencing involves integrated bulk and single-cell RNA-seq data as seen by Barrett et al. (2025) on 53 *C. elegans* neuron types. This integration improved gene detection accuracy by combining high sensitivity of bulk RNA-seq with single-cell specificity, refining transcriptional profiles and reducing false positives from contamination in scRNA-seq data. Xu et al. (2025) applied Scissor, a machine learning-based algorithm, to integrate single-cell and bulk RNA-seq data to identify survival-associated cellular states in glioblastoma. This approach inferred cell type composition and clinical relevance from bulk transcriptomes guided by single-cell references [9]. Though not explicitly a single study, the 2025 review by Barrett et al. emphasizes that recent long-read RNA sequencing approaches applied to bulk samples enhance detection of alternative splicing, isoform diversity, and allele-specific expression, crucial for comprehensive transcriptome characterization. Zhang et al. (2025) constructed a prognostic model integrating bulk RNA-seq, scRNA-seq, and clinical data in hepatocellular carcinoma. Using machine learning, they linked T cell marker gene expression from single-cell data with clinical bulk RNA profiles to predict patient outcomes, showing computational annotation and integration [10].

In conclusion, bulk RNA sequencing remains a fundamental and widely used transcriptomics tool for tissue-level gene expression profiling, especially when cost and simplicity are prioritized. However, its limitations in cellular resolution have driven the development of complementary technologies like single-cell and spatial transcriptomics for more detailed molecular dissection at the cellular level.

1. **Single Cell RNA Sequencing**

Single – cell RNA sequencing is an advanced approach for the transcriptomic analysis where the RNA molecules from a single cell of the population are isolated and sequenced using the next generation sequencing techniques. This will enable the researchers to visualize and analyze the critical functionalities and behaviors of the cell at molecular level and to differentiate between the cells of the same population. The transcriptome of a cell can reveal the state and identity of that cell in the given condition and time since RNA acts as cell’s regulatory molecules, messengers and essential component in housekeeping genes (12).The pioneering techniques to analyze transcriptomes at single cell level were relied on Fluorescent microscopic techniques which limited to only few genes (12). The emergence of Single-cell RNA sequencing was after the advancement made in probe dependent single-cell qPCR where the gene expression analysis is performed on single-cell (11). The transcriptomes developed by scRNA sequencing were first published by *Tang et al* in 2009. The probe independent scRNA sequencing involves the following stages starting with isolation single cells, cell lysis, conversion of scRNA to cDNA by reverse transcription, bar-coding of DNA, Library preparation - amplification of cDNA through PCR, sequencing and data analysis(12).

*Why is scRNA sequencing better than other techniques?*

By far, to study and analyze the single-cell gene expression qRT- PCR is preferred, but it has some limitations like confinement to specific set of genes chosen by the experimentalists while microarray enables the transcriptome profiling, the requirement of probes and huge starting amounts of RNA make it very expensive. Therefore, scRNA sequencing best replaces the pioneering techniques to study transcriptomes at the single-cell level.

1. **Applications**

***Oncogenic analysis**:* The application of scRNA sequencing in tumor has revealed the existence of transcriptional heterogeneity in cancer cells, for example, in melanoma the scRNA sequencing of CD45+ and CD45- cells is having different T cell exhaustion programs, a significant finding that is helpful for proper immunotherapy treatments (13).

***Immune cell analysis***: Cells having the same genetic content but shows differential gene expression when assessed through scRNA sequencing. When the different population of dendritic cells is taken for scRNA sequencing and analyzed the expression levels of transcripts in individual cells of both populations, it is evident that the expression of housekeeping genes is higher in one subset compared to the other. This finding is also validated by SMART sequencing and RNA FISH techniques (12).

***Embryogenic development***: scRNA sequencing becomes crucial when the biological material available for analysis is very limited such as during embryogenic development. The whole genome expression analysis of the embryonic cells has provided valuable insights about the development of embryos after fertilization and allows researchers to predict further events in developmental embryos (11).

***Stem cell differentiation*:** Differentiation of stem cells form the basis of organ development and it starts from a single cell; hence analysis of stem cells at single cell level will help to follow the trajectory of molecular markers at different stages of organ development. In the development of murine lung, previously unknown lineage specific markers in different subsets have been identified. Similarly, the development of skeletal muscles from primary myoblasts have shown the requirement of eight transcriptional factors to promote the expression of more than 1000 genes during the development (12).

**Bulk sequencing vs Single cell RNA sequencing**

Bulk RNA sequencing: The conventional bulk RNA sequencing is the replacement of microarray technique in the late 2000s before the advancement of scRNA technique. Bulk sequencing of RNA is profiling the transcriptomes from the bulk population of cells; it will give the measurement of average transcript of the population (13). But, it fails to provide subtle and biologically significant differences between cells of the same population (12). The bulk sequencing will not be able to detect the precise characterization of the subsets population of the cells with respect to its microenvironment (14).

scRNA sequencing: To understand the differential gene expression between the cells and genetic heterogeneity at transcriptome level, scRNA sequencing is the promising approach (12,14). Also, the scRNA technique helps to elucidate the behavior of the cell in response to its microenvironment (14). It can give additional and different dimensionalities to the complete genome profile of a cell than bulk sequencing (14). The sample collection for bulk sequencing can be done on tissues while scRNA requires viable cellular suspension and for scRNA the analysis must be completed within a few days of sample collection since the viability of samples may get affected. The cost involved in scRNA is huge compared to bulk sequencing due to the requirement of good quality RNA (14).

**5. Experimental Workflow Overview**

*1. Introduction*

RNA sequencing (RNA-Seq) has revolutionized transcriptomic research by enabling the comprehensive and quantitative analysis of RNA molecules within a biological sample. It provides deep insights into gene expression dynamics, alternative splicing, and novel transcript discovery. This article outlines the experimental workflow of RNA-Seq, detailing each stage from RNA extraction to computational data analysis, highlighting the rationale and importance of each step. Using the study of 17β-estradiol-treated versus control samples described (15,16) as an example, the article illustrates how RNA-Seq can elucidate differential gene expression patterns and biological responses with high accuracy and resolution.

The emergence of next-generation sequencing (NGS) technologies has dramatically enhanced our ability to analyze entire transcriptomes with high throughput and precision. RNA sequencing (RNA-Seq) allows for the direct quantification of messenger RNA (mRNA) and other RNA species, providing a digital readout of gene expression levels. Compared to earlier methods such as microarrays, RNA-Seq offers broader dynamic range, greater sensitivity, and the ability to identify novel transcripts and splice variants. An illustrative example (15,16) how RNA-Seq can be applied to study the effects of 17β-estradiol treatment on gene expression in human cells. The following sections describe the complete experimental flow, combining both wet-lab procedures and computational analysis, emphasizing the significance and purpose of each stage.

*2. Experimental Workflow and Stepwise Importance*

This section outlines each experimental step in RNA-Seq, explaining its purpose and significance. Each stage contributes to generating high-quality, reproducible transcriptomic data.

*Step 1: RNA Sample Preparation*

High-quality total RNA is the foundation for a successful RNA-Seq experiment. RNA integrity should be verified using an Agilent Bioanalyzer to ensure an RNA Integrity Number (RIN) ≥ 8. High-quality RNA reduces bias during sequencing and improves reproducibility (17). Samples are typically derived from control and treatment groups, such as cells treated with 17β-estradiol (21).

*Step 2: mRNA Purification*

Messenger RNA (mRNA) is isolated from total RNA using oligo(dT) magnetic beads, which selectively bind polyadenylated RNA molecules (22). This purification removes ribosomal and transfer RNAs, ensuring enrichment of coding transcripts essential for downstream analysis. Proper washing and elution steps prevent contamination and maintain yield (23).

*Step 3: RNA Fragmentation*

The purified mRNA is fragmented into smaller pieces (approximately 200–300 nucleotides) to facilitate uniform sequencing coverage (24). Fragmentation is achieved by heating RNA in the presence of divalent metal cations. Fragment size influences mapping quality and read alignment (25).

*Step 4: cDNA Synthesis*

First-strand cDNA is synthesized from fragmented RNA using reverse transcriptase and random hexamers (26). This step is followed by second-strand synthesis, generating double-stranded cDNA that serves as the template for library preparation. The integrity of this step determines accuracy in transcript reconstruction (27).

*Step 5: End Repair and Adapter Ligation*

The double-stranded cDNA ends are repaired to create blunt ends, followed by the addition of an adenine (A) base at the 3′ ends (28). Sequencing adapters compatible with Illumina platforms are ligated to both ends of the cDNA fragments. This step enables amplification and subsequent binding of fragments to the sequencing flow cell (29).

*Step 6: Library Amplification and Quality Assessment*

The adapter-ligated cDNA is amplified via PCR to enrich for fragments containing correct adapters (30). Over-amplification should be avoided to minimize PCR bias. Library quality is assessed using an Agilent Bioanalyzer, which ensures fragment sizes are within 200–500 bp (10). Accurate quantification is essential for successful sequencing.

*Step 7: Sequencing*

Sequencing is performed on an Illumina platform, generating millions of short reads per sample (21). The reads represent cDNA fragments derived from RNA molecules, providing quantitative and qualitative information on transcript expression levels across the genome (15,18).

*Step 8: Data Quality Control*

Raw sequencing data undergo quality assessment using tools like FastQC and MultiQC to detect adapter contamination, base quality, and GC bias (23-25). Fastp is commonly used for trimming low-quality bases and adapters, ensuring clean reads for alignment (26). These steps are critical to prevent misinterpretation of sequencing results.

*Step 9: Read Alignment and Quantification*

High-quality reads are aligned to a reference genome using alignment tools such as QuasR, which incorporates Rbowtie and SpliceMap (31). Aligned reads are quantified against gene features using Bioconductor packages, providing raw counts or normalized expression metrics such as RPKM, FPKM, or TPM (18,19).

*Step 10: Differential Expression Analysis*

Statistical analysis identifies differentially expressed genes (DEGs) between control and treatment groups (32,33). Tools like DESeq and edgeR apply models based on the negative binomial distribution to determine significant changes in expression (33,34). Genes with |log₂ fold change| ≥ 1 and adjusted p-value ≤ 0.05 are considered significantly differentially expressed.

*Step 11: Visualization and Interpretation*

DEG results can be visualized through heatmaps, clustering, and principal component analyses to reveal transcriptional patterns (27,28). Such visualizations help identify co-regulated gene sets and biological pathways influenced by treatments like 17β-estradiol exposure.

` `**6. What is Big Data? Its application, volume, variety and velocity**

`  `*I. Introduction*

The digital revolution has led to an unprecedented explosion of data generated from multiple sources—ranging from consumer interactions and business transactions to medical records and scientific research outputs. The term Big Data Analytics (BDA) refers to the use of computational methods, algorithms, and technologies that collect, process, and interpret massive and complex datasets to reveal patterns, correlations, and actionable insights (35,36). Over the past two decades, advances in hardware, cloud infrastructure, and artificial intelligence have enabled organizations to operationalize big data at scale (36). In scientific domains, particularly omics sciences—such as genomics, transcriptomics, proteomics, and metabolomics—data generation from high-throughput technologies has reached terabyte and petabyte scales, necessitating the use of big data analytics for integration, interpretation, and application (37–40). Big data analytics not only drives innovation in business but also transforms biomedical research, where it underpins the identification of biomarkers, disease mechanisms, and personalized therapies (37,38,40).

*II. What is Big Data Analytics?*

Big Data Analytics (BDA) is the process of collecting, examining, and analyzing vast amounts of structured and unstructured data to uncover trends, insights, and patterns that inform strategic decision-making (35,36). BDA employs statistical and computational techniques such as clustering, regression, and predictive modeling, applied to large-scale datasets using tools like Hadoop, Spark, and NoSQL databases (35,36). The nature of big data is defined by the five Vs:\
` `• Volume: The sheer magnitude of data—ranging from terabytes to zettabytes—generated continuously (35,36).\
` `• Variety: The heterogeneity of data, including structured, unstructured, and semi-structured formats (35).\
` `• Velocity: The high speed at which data is generated and processed, enabling both batch and real-time analysis (35,36).\
` `• Veracity: The reliability, accuracy, and trustworthiness of the data (35).\
` `• Value: The actionable insights derived from data that create business or scientific impact (35,36).

*III. Framework of Big Data Analytics*

The framework of big data analytics comprises four primary stages that transform raw data into valuable insights (35,36):

1\.Data Collection: Data is collected from multiple sources—IoT sensors, online transactions, clinical systems, or experimental devices—and stored in data warehouses (for structured data) or data lakes (for raw or unstructured data) (35,36).

2\.Data Processing: Collected data must be processed to enable accurate querying and analysis. Two major techniques are used: batch processing for long-term trends and stream processing for real-time decision-making (35).

3\.Data Cleaning: Data scrubbing removes errors, duplicates, and inconsistencies, ensuring high-quality, reliable results (35,36).

4\.Data Analysis: Analytical methods—ranging from descriptive statistics to machine learning—are applied to extract knowledge (35).

*IV. Big Data in Omics: A Specialized Application*

In the life sciences, omics fields—such as genomics, transcriptomics, proteomics, and metabolomics—are characterized by high-dimensional, heterogeneous, and large-scale datasets produced by high-throughput experiments (37,38). These datasets represent a major challenge for computational biology, as traditional analytical tools are insufficient to handle their complexity and scale (37,38). Integration of multiple omics datasets (multi-omics integration) provides a holistic view of biological processes and helps reveal interrelationships among biomolecules (37,38). Subramanian et al. (37) emphasized that combining data across multiple molecular layers enhances understanding of disease mechanisms, enables precise patient stratification, and supports biomarker discovery. Cloud computing has emerged as a low-cost, scalable, and flexible solution for storing and analyzing such data (39). Machine learning (ML) and deep learning (DL) algorithms are central to these analyses, offering predictive modeling and pattern recognition capabilities in high-dimensional datasets (38,40).


*V. Tools and Technologies*

Big data analytics leverages a diverse ecosystem of tools to manage large-scale datasets across industries and research fields (35,36,39):

|Tool / Platform|Description / Functionality|
| :- | :- |
|Hadoop|Open-source framework for distributed storage and processing using clusters (35,36).|
|MapReduce|Framework for mapping and reducing data across clusters (35).|
|YARN|Cluster management for job scheduling and resources (35).|
|Spark|Open-source engine for real-time analytics (35,36).|
|NoSQL Databases|Flexible schema-free systems for unstructured data (35).|
|Tableau|Visualization and self-service analytics platform (35).|
|TBtools-II|Bioinformatics platform for multi-omics big-data mining (41).|
|Cloud Computing Frameworks|Enable distributed analysis and scalability (39).|

*VI. Benefits of Big Data Analytics*

Big data analytics drives innovation across business and scientific landscapes (35,36):\
` `• Cost Savings: Streamlining operations through efficiency-driven insights (35).\
` `• Product Development: Using analytics to understand customer or biological system needs (35,36).\
` `• Strategic Decision-Making: Faster and more informed decisions (35).\
` `• Predictive Insights: Anticipating outcomes such as disease risk (37,38).\
` `• Personalized Solutions: Powering precision medicine (3,5).\
` `• Scientific Discovery: Enabling modeling of complex biological systems (38,40).

*VII. Challenges of Big Data Analytics*

While big data analytics offers immense benefits, several challenges persist (35,36,38,39):\
` `• Data Accessibility: Making big data usable for stakeholders (35).\
` `• Data Quality: Maintaining accuracy and consistency (35).\
` `• Privacy and Security: Protecting sensitive biomedical data (36).\
` `• Computational Scalability: Managing high-performance needs (39).\
` `• Interoperability: Integrating diverse tools and formats (50).\
` `• Skill Gaps: Bridging expertise between data science and domain knowledge (38,50).


*VIII. Applications and Future Prospects*

Big data analytics has reshaped industries from finance to healthcare. In the biomedical domain, it plays a transformative role in precision medicine, biomarker discovery, and public health (37,38,40). Future prospects include AI-driven multi-omics integration, quantum computing for biological simulations, and blockchain technologies for secure biomedical data sharing (40,41).

*IX. Conclusion*

Big data analytics has revolutionized data utilization across sectors. In omics research, it enables the integration and interpretation of vast, complex datasets to derive meaningful insights. By combining cloud computing, artificial intelligence, and machine learning, big data analytics empowers scientists and organizations to make data-driven decisions. However, realizing its full potential requires addressing standardization, data security, and interdisciplinary collaboration challenges. Advances in scalable computational infrastructures and AI-powered analytics promise to further accelerate innovation and discovery.

**7.  Homogeneity vs Heterogeneity of Data**

*I. Introduction*

Biological data are inherently complex, reflecting the immense diversity and variability of life processes at molecular, cellular, and organismal levels. This complexity is mirrored in data generated by high-throughput omics technologies and biomedical imaging, which capture biological systems with varying degrees of precision and scale. Understanding the homogeneity (uniformity) and heterogeneity (diversity) of biological data is essential for interpreting variability across individuals, tissues, and populations, and for linking this variability to meaningful biological insights.

In the context of big data analytics, homogeneity and heterogeneity are not merely statistical properties—they represent biological realities. Biological systems are heterogeneous by design, and simplifying them into homogeneous models can obscure important mechanistic and clinical insights (42–44).

*II. Defining Homogeneity and Heterogeneity in Data*

Homogeneity refers to uniform or consistent data points that share similar statistical or biological characteristics. For instance, homogeneous datasets assume that individuals or samples respond similarly to perturbations or treatments. This assumption simplifies modeling but risks oversimplifying biological complexity (45).

Heterogeneity, conversely, refers to diversity or variability among data points. In biological systems, heterogeneity manifests at multiple scales—genetic polymorphisms, transcriptomic variation, differential protein expression, and variable metabolic profiles (43,46). It represents both a challenge (noise, confounding variability) and an opportunity (source of personalized insights and disease subtyping).

In data science, heterogeneity complicates data integration, model training, and prediction. However, it is also biologically informative—capturing variation between healthy and diseased states or between subtypes of disease (46,47).

*III. Biological Variability as the Root of Data Heterogeneity*

Biological heterogeneity arises naturally from genetic, environmental, and stochastic influences. In omics research, every individual carries a unique combination of genomic variants, epigenetic modifications, and gene expression profiles. This leads to high-dimensional, multi-modal datasets, where each layer of data (genomics, transcriptomics, proteomics, metabolomics) introduces its own variability (44,46,48).

For example, Feczko and Fair (2020) emphasize that psychiatric and neurological disorders cannot be treated as homogeneous entities; rather, they are composed of multiple subtypes driven by discrete mechanisms (47). Similarly, in cancer biology, intratumoral heterogeneity—genetically distinct clones within the same tumor—complicates diagnosis and treatment but also provides opportunities for targeted therapies (46).

*IV. The Homogeneity-Heterogeneity Spectrum in Biological Data*

Biological systems are inherently dynamic and varied. The way a sample is collected and processed dictates whether this natural variability is captured or masked in the final dataset.

*IV.I Homogeneous Data (Bulk Samples)*

Homogeneous data is typically generated from bulk tissue or cell line samples (42). When a sample is collected in bulk, such as a standard tissue biopsy or traditional omics sequencing, data is generated from thousands or millions of cells simultaneously. This produces an averaged, uniform signal representing the mean expression level, mutation frequency, or metabolic state across all cells in the sample (42).

However, this averaging masks critical information about rare or specialized cell types, leading to a loss of biological resolution. Thus, while bulk data provides a general overview, it cannot accurately represent the underlying complexity of biological systems (42).

*IV.II Heterogeneous Data (Single-Cell Technologies)*

Heterogeneous data, on the other hand, captures biological variation at the single-cell level through advanced techniques such as single-cell RNA sequencing (scRNA-seq) (42,43,44). These technologies isolate and analyze the genome, transcriptome, or proteome of individual cells, revealing distinct subtypes, cell states, and trajectories within a tissue (45).

This high-dimensional data provides a more comprehensive picture of biological processes, enabling a deeper understanding of cellular heterogeneity, disease mechanisms, and developmental biology (45).

*V. Data Complexity and Big Data Challenges*

The complexity of biological heterogeneity scales exponentially with modern big data generation. In omics and systems biology, data heterogeneity arises from technical, biological, and environmental variability, such as batch effects, tissue differences, or lifestyle factors. Such heterogeneity introduces challenges for reproducibility and data integration. Big Data Analytics frameworks—such as cloud computing and machine learning—offer scalable solutions but require careful normalization and annotation to maintain biological fidelity (44,45,46).

*VI. Why Heterogeneity Matters in Biomedical Analysis*

The ability to resolve and analyze cellular heterogeneity is paramount for transforming large-scale omics data into clinically actionable insights (46).

*VI.I Understanding Disease Pathogenesis and Subtyping*

Diseases such as cancer and neurodegenerative disorders are inherently heterogeneous. Tumors, for instance, contain a mosaic of malignant, immune, and stromal cells with unique molecular signatures (43). Bulk analysis often averages these signals, potentially leading to misclassification. Single-cell approaches enable the identification of novel subtypes and the cellular origins of metastasis or therapy resistance (45).

*VI.I Deciphering Immune Response*

The immune system’s complexity arises from diverse immune cell types that continuously transition between functional states. Heterogeneous data reveals how rare subsets of immune cells drive disease progression or therapeutic efficacy—insights that bulk datasets cannot capture (43).

*VI.I Addressing Drug Resistance*

Drug resistance often stems from minor sub-populations of cells that survive initial treatment and expand under selective pressure (43). Analyzing heterogeneity enables detection of these rare resistant clones and supports the design of multi-omics-guided combination therapies (45,47).

*VII. Statistical and Computational Frameworks for Managing Heterogeneity*

Modern computational biology employs a range of methods to model and manage biological heterogeneity, including bifactor models, normative modeling, and functional random forests (47). These approaches, along with multi-omics integration tools such as MOFA+, DIABLO, and TBtools-II, allow researchers to identify complex patterns and relationships within high-dimensional data (45,48).

*VIII. Conclusion*

The balance between homogeneity and heterogeneity represents a central challenge in biological data analysis. Homogeneous data enables statistical simplicity, but heterogeneous models capture the biological reality of dynamic, multi-scale systems. Big Data Analytics, AI-driven modeling, and multi-omics integration are bridging this divide, turning biological variability into actionable insights for precision medicine. Embracing heterogeneity is not only a computational challenge but a biological necessity for advancing biomedical discovery.

**8. Tools for Data Analysis in Bulk and Single-Cell RNA Sequencing**

*Introduction*

RNA sequencing (RNA-seq) has transformed transcriptomic research by enabling genome-wide profiling of gene expression. Two major modalities—bulk RNA sequencing (bulk RNA-seq) and single-cell RNA sequencing (scRNA-seq)—serve different analytical goals. Bulk RNA-seq provides an averaged expression profile across a population of cells, whereas scRNA-seq captures transcriptional variation at the individual cell level (49,50). Each approach employs specialized bioinformatics tools for quality control, alignment, quantification, and downstream analysis. This essay describes the major computational tools used in both bulk and single-cell RNA-seq workflows, explaining their roles and providing examples from recent studies.

*1. Tools for Bulk RNA-Seq Data Analysis*

Bulk RNA-seq analysis involves multiple computational steps, each essential for ensuring the accuracy and interpretability of expression data. The major phases include quality control, sequence alignment, transcript quantification, and differential expression analysis (51).

*1.1 Quality Control and Preprocessing*

Raw sequencing reads are first subjected to quality assessment and trimming. Tools such as “FastQC” and “MultiQC” are widely used for this purpose (52,53). FastQC provides visual summaries of sequence quality, GC content, and duplication rates, while MultiQC aggregates multiple reports into a single dashboard. For adapter and low-quality base removal, “Trimmomatic” and “fastp” are common choices (54,55). Fastp integrates filtering, trimming, and quality control into a single fast and lightweight pipeline.

*1.2 Sequence Alignment*

After preprocessing, reads are aligned to a reference genome or transcriptome using “HISAT2”, “STAR”, or “TopHat2”, which are splice-aware aligners suitable for eukaryotic RNA (56–158). STAR is particularly known for its high speed and accuracy in detecting splice junctions, while HISAT2 offers memory efficiency and scalability for large datasets.

*1.3 Transcript Assembly and Quantification*

Aligned reads can be assembled into transcripts using “StringTie” or “Cufflinks”, while de novo transcriptome assembly is performed with “Trinity” in the absence of a reference genome (59–61). For quantification, lightweight methods such as “Salmon” and “Kallisto” employ pseudo-alignment to rapidly estimate transcript abundances with high accuracy (62,63). These tools significantly reduce computational time compared to traditional alignment-based methods.

*1.4 Differential Expression Analysis*

To identify differentially expressed genes (DEGs) between conditions, statistical tools like “DESeq2”, “edgeR”, and “limma-voom” are used (64–66). These packages apply rigorous normalization and modeling approaches to account for biological and technical variability. For instance, DESeq2 employs shrinkage estimation to improve fold-change accuracy for low-count genes.

*2. Tools for Single-Cell RNA-Seq Data Analysis*

Single-cell RNA sequencing (scRNA-seq) presents additional challenges such as high sparsity, technical noise, and large data volumes (67). Specialized tools address these through tailored preprocessing, normalization, and clustering workflows (68).

*2.1 Preprocessing and Alignment*

Initial quality control is again performed using “FastQC” and “fastp” (69). Barcode-aware alignment tools such as “Cell Ranger”, “STARsolo”, “Alevin”, and “Kallisto-bustools” handle demultiplexing, Unique Molecular Identifier (UMI) correction, and read mapping (70–73). For example, Cell Ranger, developed by 10x Genomics, streamlines preprocessing for droplet-based scRNA-seq data.

*2.2 Quantification and UMI Processing*

To correct amplification bias and ensure accurate molecule counting, UMI-based tools such as “UMI-tools”, “scPipe”, and “zUMIs” are employed (74–76). These tools remove PCR duplicates and generate precise gene-level count matrices.

*2.3 Normalization, Clustering, and Visualization*

Normalization methods including “scran” and “SCTransform” adjust for sequencing depth and technical effects (77). For clustering and visualization, integrated frameworks like “Seurat” and “SCANPY” are widely used (78,79). Seurat offers advanced integration and trajectory inference capabilities, while SCANPY efficiently handles large-scale datasets in Python environments.

*2.4 Differential Expression and Trajectory Analysis*

Differential expression at single-cell resolution is typically analyzed using “MAST”, “DEsingle”, or “SCDE”, which model zero inflation and high noise (80–82). Trajectory inference tools such as “Monocle”, “Slingshot”, and “PAGA” reconstruct cell lineages and developmental trajectories (83–85). These algorithms are pivotal in understanding dynamic processes like differentiation and tumor progression.

*3. Comparison Between Bulk and Single-Cell RNA-Seq Workflows*

While bulk RNA-seq tools like STAR, StringTie, and DESeq2 are optimized for population-level expression profiling, scRNA-seq tools such as Seurat and SCANPY enable dissection of cellular heterogeneity. Bulk approaches are more cost-effective and statistically robust for large cohorts, whereas single-cell approaches provide unprecedented insights into cell-specific regulatory mechanisms (86).

*Conclusion*

RNA sequencing continues to evolve as a cornerstone of transcriptomics. From FastQC and HISAT2 in bulk workflows to Cell Ranger and Seurat in single-cell pipelines, each tool contributes to generating biologically meaningful insights. As computational efficiency and statistical rigor improve, integrative multi-omics frameworks promise deeper understanding of gene regulation at both tissue and cellular resolution (87).

**9. Tools for RNA sequencing**

RNA sequencing (RNA-seq) is a central technology for transcriptome analysis, providing comprehensive insights into gene expression and regulation across diverse biological systems. Two major sequencing strategies are widely adopted: bulk RNA-seq, which captures the average transcriptional profile of a cell population, and single-cell RNA sequencing (scRNA-seq), which enables expression profiling at single-cell resolution to uncover cellular heterogeneity. Each approach requires specialized computational pipelines to transform raw sequencing reads into biologically meaningful information.

In bulk RNA-seq, computational workflows typically include stages of quality control, alignment, and differential expression analysis. Tools such as *FastQC* and *Trimmomatic* are used for assessing and improving data quality, while aligners like *STAR* and *HISAT2* efficiently map reads to reference genomes. Statistical packages such as *DESeq2* and *edgeR* then model expression data to identify differentially expressed genes between experimental conditions. Early automation efforts, exemplified by ArrayExpressHTS (88), established integrated pipelines within the Bioconductor ecosystem, emphasizing usability and reproducibility through standardized workflows and EBI cloud execution.

In contrast, scRNA-seq introduces unique computational challenges related to data sparsity and scale. Preprocessing tools such as *Cell Ranger* handle barcode assignment, alignment, and quantification to generate cell-by-gene expression matrices. Downstream analysis frameworks, including *Seurat* (R) and *Scanpy* (Python), perform normalization, clustering, and visualization using dimensionality-reduction techniques such as *t-SNE* and *UMAP*. More advanced tools like *Monocle* and *SCENIC* enable trajectory inference and gene regulatory network reconstruction, respectively. Pipelines such as aRNApipe (89) and pyrpipe (90) exemplify the evolution of RNA-Seq analysis toward high-performance, modular, and reproducible frameworks. *aRNApipe* focuses on distributed computation in high-performance computing (HPC) environments, whereas *pyrpipe* introduces an object-oriented Python interface that promotes flexibility, transparency, and seamless integration with workflow managers like Snakemake or Nextflow.

As RNA-seq and scRNA-seq technologies continue to generate increasingly large and complex datasets, the demand for HPC and cloud computing infrastructures has become crucial for scalable, efficient, and reproducible analysis. The progression from early cloud-based automation (*ArrayExpressHTS*) to HPC-optimized workflows (*aRNApipe*) and modern reproducible programming frameworks (*pyrpipe*) reflects the broader shift in transcriptomic data analysis toward open, modular, and sustainable computational practices.

*General Comparison*

|Feature|ArrayExpressHTS (2011)|aRNApipe (2017)|pyrpipe (2021)|
| :- | :- | :- | :- |
|Language|R / Bioconductor|Python 2.7|Python 3|
|Scalability|Limited / EBI Cloud|High / HPC|High / HPC + Workflow managers|
|Modularity|Moderate|High|Very high (Object-Oriented APIs)|
|Reporting|Basic HTML|Interactive web (Spider)|JSON + MultiQC|
|Flexibility|Low (fixed configuration)|Moderate (centralized configuration)|High (YAML + Python)|
|Reproducibility|Moderate|High|Very high (logs, YAML, Git integration)|
|Target Users|R users|Bioinformaticians using HPC|Developers and computational biologists using Python|

-----
The evolution of RNA-Seq computational pipelines demonstrates a clear transition from basic automation and remote access (*ArrayExpressHTS*), to efficient resource management and scalability in HPC environments (*aRNApipe*), culminating in modern solutions centered on reproducibility, modularity, and code portability (*pyrpipe*). Together, these tools have played a crucial role in democratizing transcriptomic data analysis, adapting to the exponential growth of sequencing data and aligning with the principles of open and reproducible science.

**10. Example of diseases from a certain tissue or cell** 

Diseases often originate from abnormalities in specific tissues or cell populations, and understanding these cellular variations is crucial for elucidating disease mechanisms [91]. Single-cell RNA sequencing (scRNA-seq) has emerged as a transformative technology for profiling gene expression at single-cell resolution, enabling researchers to explore cellular heterogeneity within tissues affected by cancer, neurodegenerative, autoimmune, and infectious diseases [92].

In cancer, scRNA-seq provides insights into tumor heterogeneity, identifying subclonal populations that drive therapy resistance and relapse. It also enables characterization of the tumour microenvironment (TME), including infiltrating immune and stromal cells that influence tumour progression [93]. For instance, in breast cancer, scRNA-seq has revealed distinct tumour subpopulations with varying proliferative and metastatic potentials [94]. Gu et al., [95] demonstrated that malignant epithelial cells exhibit transcriptional plasticity and interact dynamically with immune and fibroblast cells, shaping the immunosuppressive TME. This cellular mapping has guided precision oncology by identifying novel therapeutic targets, such as immune checkpoint regulators and fibroblast activation pathways [96].

In neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, scRNA-seq uncovers neuronal subtypes and glial cells that are selectively vulnerable to degeneration. For example, single-cell analysis of the human cortex identified microglial activation states associated with amyloid pathology, providing clues about early inflammatory responses in Alzheimer’s disease [97].

Autoimmune diseases also benefit from scRNA-seq applications. In systemic lupus erythematosus and rheumatoid arthritis, the technology has revealed transcriptional diversity among T and B cells, highlighting dysregulated pathways involved in immune tolerance and autoantibody production [98]. This helps refine treatment approaches by targeting specific dysfunctional immune subsets.

During the COVID-19 pandemic, scRNA-seq has been instrumental in profiling immune responses to SARS-CoV-2 infection. It identified hyperactivated monocytes, exhausted T cells, and impaired interferon responses in severe cases, shedding light on mechanisms of immune dysregulation and potential therapeutic targets [99].

In summary, diseases arising from specific tissues or cells such as tumours, neurons, or immune cells exhibit complex heterogeneity that can now be dissected at single-cell resolution. Through scRNA-seq, researchers can map cellular networks, uncover disease-driving pathways, and develop precision therapies that target the most relevant cell populations, advancing our understanding of human disease biology.

**11. Challenges and Limitations**

RNA sequencing (RNA-Seq), both in bulk and single-cell formats, has revolutionized transcriptomic research, enabling high-resolution insights into gene expression, cellular states, and regulatory mechanisms. Despite its transformative potential, several technical, analytical, and ethical challenges persist that influence data quality, reproducibility, and interpretability (100,101). These limitations span cost, computational demand, technical artifacts such as dropout events, batch effects, and challenges associated with integrating heterogeneous datasets. Addressing these issues is crucial for maximizing the accuracy and translational value of RNA-Seq studies.

*11.1 High Cost and Computational Demand*

The high financial and computational burden remains a primary limitation of RNA-Seq, particularly for single-cell RNA sequencing (scRNA-Seq). While the cost of bulk RNA-Seq has stabilized around USD 200–300 per sample, single-cell workflows can exceed USD 1,500 depending on cell numbers and sequencing depth (102). The need for high sequencing depth (often >50,000 reads per cell) and complex library preparation protocols—such as 10x Genomics Chromium and Smart-Seq3—further amplify costs (103). Computationally, RNA-Seq data processing involves multiple high-throughput tasks, including alignment, normalization, and clustering, which require powerful CPUs, GPUs, and large memory capacities (104). Cloud-based tools like Terra, Galaxy, and Seven Bridges are increasingly used to manage these computational loads efficiently, yet they raise concerns regarding cost scalability and data security (105).

*11.2 Dropouts and Missing Transcripts*

In single-cell RNA-Seq, dropout events—where transcripts are not detected due to low mRNA capture efficiency—create sparse and zero-inflated datasets. This can obscure biological variation and confound downstream analyses such as differential expression or trajectory inference (106). Techniques like imputation algorithms (e.g., MAGIC, scImpute, SAVER) have been developed to recover missing signals; however, these methods risk introducing artificial correlations that distort genuine biological patterns (107). For instance, in tumor heterogeneity studies, dropout correction has occasionally led to overestimation of subclone diversity, complicating the biological interpretation (108). Emerging methods such as deep generative models and transfer learning frameworks (e.g., scVI and scGPT, introduced in 2024) aim to model transcriptomic sparsity more accurately by leveraging probabilistic embeddings of single-cell data (109).

*11.3 Batch Effects and Data Integration*

Batch effects—technical variations arising from differences in library preparation, sequencing runs, or experimental batches—represent one of the most persistent analytical obstacles in RNA-Seq (110). These effects can mask true biological signals or create spurious differences between samples. Common correction tools such as ComBat, Harmony, Scanorama, and Seurat v5 integration pipelines mitigate these issues by aligning shared features across datasets (111). However, batch correction in multi-omic or cross-platform datasets (e.g., integrating RNA-Seq with ATAC-Seq or proteomics) remains complex and computationally demanding. Recent advances, including mutual nearest neighbor (MNN) algorithms and deep learning-based integrative frameworks (e.g., scJoint), have improved scalability and reproducibility, yet a universal solution for eliminating batch effects across large consortia datasets (e.g., the Human Cell Atlas) is still lacking (112).

*11.4 Scalability and Interpretation Challenges*

As RNA-Seq datasets grow exponentially—often reaching millions of single cells per experiment—the scalability of analysis pipelines becomes increasingly difficult (113). Existing tools, such as STAR, DESeq2, and edgeR, though highly reliable for bulk RNA-Seq, face limitations when applied to sparse, high-dimensional single-cell data. Similarly, visualization and clustering tools (e.g., t-SNE, UMAP) struggle with large-scale datasets, often producing unstable or biased embeddings (114). To overcome these bottlenecks, distributed computing platforms and GPU-optimized algorithms such as Scanpy 2.0, Rapids-singlecell, and BiocMAP (2024) are being adopted (115). Nevertheless, interpretative challenges remain: mapping high-dimensional clusters to biologically meaningful cell types still requires manual curation and expert domain knowledge, which limits automation and reproducibility (116).

*11.5 Ethical and Privacy Considerations*

The integration of human-derived transcriptomic data, particularly at the single-cell level, introduces ethical and privacy concerns. RNA-Seq datasets can potentially reveal individual-specific genetic variants or rare disease-associated mutations, raising questions about data sharing and informed consent (117). The General Data Protection Regulation (GDPR) and NIH Genomic Data Sharing Policy emphasize anonymization and controlled data access, yet full compliance can impede collaborative research (118). Moreover, as single-cell atlases expand to include developmental and patient-derived samples, ethical concerns also encompass equitable data representation and potential misuse in predictive medicine (119). Emerging bioethical frameworks in genomics advocate for transparent governance, participant feedback mechanisms, and privacy-preserving computation (120).

Conclusion

Despite remarkable advances, challenges in RNA-Seq—particularly in single-cell contexts—remain formidable. Addressing cost barriers, minimizing dropouts, improving data integration, and safeguarding ethical data usage are central to ensuring that transcriptomic research continues to yield reproducible and clinically meaningful insights. Progress in AI-driven modeling, cloud-based computation, and federated data sharing promises to alleviate many of these issues in the coming years (121).

**12. Future Directions: Spatial and Multi-Omics Approaches**

The field of transcriptomics is rapidly transitioning beyond conventional bulk and single-cell RNA sequencing toward spatial and multi-omics paradigms that integrate multiple molecular layers and preserve the tissue’s architectural context. These next-generation approaches promise to overcome existing limitations—such as loss of spatial information, incomplete regulatory insight, and cell-type misclassification—thereby offering a more holistic understanding of cellular function in health and disease (122,123). By combining transcriptomic, epigenomic, proteomic, and metabolic data within intact tissue environments, researchers can now decode not only what genes are expressed but also where and why they are expressed.

*12.1 Spatial Transcriptomics: Preserving Tissue Architecture*

Spatial transcriptomics (ST) represents a transformative leap in RNA sequencing by retaining the spatial organization of gene expression within tissues. Unlike traditional scRNA-seq, which dissociates cells and loses positional context, ST maps transcript abundance directly onto histological sections (124). Technologies such as 10x Genomics Visium, Slide-seqV2, and MERFISH achieve subcellular resolution by combining molecular barcoding with spatially resolved imaging (125,126). This approach has been instrumental in uncovering tumor microenvironment heterogeneity and neural circuit organization. For example, a 2024 study by Zhang et al. used spatial transcriptomics to delineate immune infiltration patterns in breast cancer, revealing localized cytokine gradients associated with treatment resistance (127). Similarly, in neuroscience, spatially resolved profiling has identified distinct neuronal subtypes within cortical layers that were indistinguishable in dissociated scRNA-seq datasets (128). Challenges persist, including limited sequencing depth per pixel and computationally intensive deconvolution algorithms (129). Nevertheless, hybrid workflows that integrate ST with single-cell RNA-seq (spatially informed scRNA-seq) are emerging to link spatial signals with transcriptional profiles, offering unprecedented tissue-level insights (130).

*12.2 Multi-Omics: Integrating Layers of Cellular Information*

Multi-omics approaches combine RNA sequencing with other molecular modalities such as chromatin accessibility (scATAC-seq), DNA methylation, proteomics, and metabolomics. This integration allows simultaneous assessment of gene expression and regulatory mechanisms, enabling a systems-level understanding of cellular states (131). For instance, joint profiling of scRNA-seq and scATAC-seq (e.g., 10x Multiome, SHARE-seq) can reveal how epigenetic landscapes govern transcriptional programs in differentiation or disease (132). Recent developments in CITE-seq and REAP-seq enable concurrent measurement of mRNA and surface protein abundance, bridging the transcript-to-protein gap (133). Similarly, metabolomics-integrated scRNA-seq workflows are emerging, enabling correlation of metabolic fluxes with gene expression at the single-cell level (134). These approaches are increasingly applied in oncology, immunology, and neurodegenerative disease research, where integrating multiple molecular dimensions has revealed mechanisms of drug resistance and immune evasion (135).

*12.3 Artificial Intelligence and Machine Learning Integration*

As multi-omic datasets grow exponentially, AI and machine learning (ML) are becoming indispensable for data interpretation. Deep learning architectures such as autoencoders, graph neural networks, and transformer-based models (e.g., scGPT and BioBERT-Omics) enable feature extraction, denoising, and prediction of unseen biological states (136). AI-driven integration frameworks like TotalVI, MOFA+, and scJoint fuse multi-modal datasets into unified latent spaces, facilitating the discovery of novel cell types and signaling pathways (137). Moreover, predictive models trained on integrated omics data are beginning to identify potential therapeutic targets and forecast patient-specific treatment responses, advancing precision medicine (138).

*12.4 Toward Precision Medicine and Personalized Therapies*

The convergence of spatial transcriptomics, single-cell sequencing, and multi-omics integration is driving the era of precision medicine. In cancer research, spatially resolved single-cell profiling allows clinicians to visualize tumor evolution and identify microenvironment-specific vulnerabilities (139). Similarly, in regenerative medicine, spatial and temporal mapping of gene expression guides the optimization of stem cell therapies and tissue engineering (140). Future clinical applications may involve personalized omics maps, where integrated genomic, transcriptomic, and proteomic data inform individualized treatment regimens (141). Efforts like the Human Cell Atlas and NIH Bridge2AI initiatives aim to build standardized, interoperable datasets combining spatial and multi-omic layers, laying the foundation for AI-assisted diagnostics and therapeutic design (142,143). As technologies continue to mature, these integrated frameworks will redefine our understanding of molecular pathology and accelerate the translation of omics research into actionable medical insights.

*Conclusion*

The advent of single-cell RNA sequencing (scRNA-seq) has fundamentally transformed the landscape of molecular biology, shifting the paradigm from population-level gene expression profiling to the resolution of individual cellular identities. Each cell, once considered a uniform component within a tissue, is now recognized as a unique entity with its own transcriptional signature, developmental trajectory, and functional role. This revolution has revealed that biological systems—whether in the brain, immune system, or tumor microenvironment—are mosaics of diverse cell types and states, each contributing to the overall behavior of the organism.

By decoding the transcriptomes of thousands of single cells simultaneously, scRNA-seq allows researchers to uncover hidden heterogeneity, identify rare cell populations, and reconstruct cellular differentiation pathways that were previously masked in bulk analyses. Such high-resolution insight is invaluable for understanding disease mechanisms, as it enables the dissection of complex pathologies like cancer, autoimmune disorders, and neurodegenerative diseases at a cellular level. For instance, scRNA-seq has exposed how distinct tumor subclones drive therapy resistance, how immune cells adopt specialized activation states during infection, and how neuronal populations degenerate selectively in neurological disorders.

Beyond basic discovery, single-cell transcriptomics now underpins the rise of precision medicine, where therapies are informed by the molecular profiles of individual cells rather than averaged tissue signals. The integration of scRNA-seq with spatial transcriptomics and multi-omics approaches—such as scATAC-seq, proteomics, and metabolomics—has further expanded our ability to map not only what genes are expressed, but also where and why they are expressed in the tissue context. When coupled with artificial intelligence and big data analytics, these multi-dimensional datasets are beginning to predict disease trajectories, patient outcomes, and therapeutic responses with remarkable accuracy.

In essence, scRNA-seq has given life to the idea that “one cell can tell a thousand stories.” Each transcript captured from a single cell adds a new chapter to our understanding of biology, revealing the intricate orchestration of gene expression that defines cellular identity, communication, and function. As technology continues to evolve, integrating spatial and temporal dimensions with artificial intelligence, single-cell transcriptomics will not only continue to illuminate the complexity of life at the smallest scale but also pave the way for personalized, cell-informed therapies that redefine the future of human health.

**References**

1. Lister R, O'Malley RC, Tonti-Filippini J, Gregory BD, Berry CC, Millar AH, et al. Highly integrated single-base resolution maps of the epigenome in Arabidopsis. Cell. 2008;133(2):523-36. 
1. Nagalakshmi U, Wang Z, Waern K, Shou C, Raha D, Gerstein M, et al. The transcriptional landscape of the yeast genome defined by RNA sequencing. Science. 2008;320(5881):1344-9. 
1. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008;5(7):621-8. 
1. Holt RA, Jones SJ. The new paradigm of flow cell sequencing. Genome Res. 2008;18(7):839-46. 
1. Hegenbarth J-C, Lezzoche G, De Windt LJ, Stoll M. Perspectives on Bulk-Tissue RNA Sequencing and Single-Cell RNA Sequencing for Cardiac Transcriptomics. Frontiers in Molecular Medicine. 2022;Volume 2 - 2022.
1. Wang Y, Mashock M, Tong Z, Mu X, Chen H, Zhou X, et al. Changing Technologies of RNA Sequencing and Their Applications in Clinical Oncology. Front Oncol. 2020;10:447.
1. Barrett A, Varol E, Weinreb A, Taylor SR, McWhirter RM, Cros C, et al. Integrating bulk and single cell RNA-seq refines transcriptomic profiles of individual C. elegans neurons. eLife Sciences Publications, Ltd; 2025.
1. ` `Li X, Wang C-Y. From bulk, single-cell to spatial RNA sequencing. International Journal of Oral Science. 2021;13(1):36.
1. Xu Z, Xi B, Huang J, Zhang L, Cui S, Wang X, et al. Integration of Single-Cell RNA and Bulk RNA Sequencing Reveals Cellular Heterogeneity and Identifies Survival-Associated Regulatory Networks in Glioblastoma. IET Syst Biol. 2025;19(1):e70025.
1. Zhang Y, Zhang H, Liu L. Integration of single-cell and bulk RNA sequencing identifies and validates T cell-related prognostic models in hepatocellular carcinoma. PLOS ONE. 2025;20(5):e0322706.
1. Kolodziejczyk AA, Kim JK, Svensson V, Marioni JC, Teichmann SA. The technology and biology of single-cell RNA sequencing. Molecular cell. 2015 May 21;58(4):610-20.
1. Saliba AE, Westermann AJ, Gorski SA, Vogel J. Single-cell RNA-seq: advances and future challenges. Nucleic acids research. 2014 Aug 18;42(14):8845-60.
1. Kashima, Y., Sakamoto, Y., Kaneko, K. *et al.* Single-cell sequencing techniques from individual to multiomics analyses. *Exp Mol Med* **52**, 1419–1427 (2020).
1. Kuksin M, Morel D, Aglave M, Danlos FX, Marabelle A, Zinovyev A, Gautheret D, Verlingue L. Applications of single-cell and bulk RNA sequencing in onco-immunology. European journal of cancer. 2021 May 1;149:193-210.
1. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57–63.
1. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet. 2011;12:87–98.
1. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008;18(9):1509–1517.
1. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-seq. Nat Methods. 2008;5(7):621–628.
1. Twine NA, Janitz K, Wilkins MR, Janitz M. Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer’s disease. PLoS One. 2011;6(1):e16266.
1. Eksi R, Li HD, Menon R, et al. Systematically differentiating functions for alternatively spliced isoforms through integrating RNA-seq data. PLoS Comput Biol. 2013;9(11):e1003314.
1. Illumina Inc. mRNA sequencing overview. Available from: http://www.illumina.com/applications/sequencing/rna/mrna-seq.html
1. Liang H, Zeng E. RNA-seq experiment and data analysis. Methods Mol Biol. 2016;1366:99–114.
1. Leggett RM, Ramirez-Gonzalez RH, Clavijo BJ, Waite D, Davey RP. Sequencing quality assessment tools to enable data-driven informatics for high throughput genomics. Front Genet. 2013;4:288.
1. Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010. Available from: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
1. Ewels P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32(19):3047–3048.
1. Chen S, Zhou Y, Chen Y, Gu J. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884–i890.
1. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
1. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-Seq quantification. Nat Biotechnol. 2016;34(5):525–527.
1. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference. Nat Methods. 2017;14(4):417–419.
1. Gaidatzis D, Lerch A, Hahne F, Stadler MB. QuasR: quantification and annotation of short reads in R. Bioinformatics. 2014;30(9):1347–1349.
1. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.
1. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140.
1. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. Genome Biol. 2014;15:550.
1. Eyster KM, ed. Estrogen Receptors: Methods and Protocols. Methods in Molecular Biology, vol 2418. Springer; 2022.
1. What Is Big Data Analytics? Definition, Benefits, and More [Internet]. Coursera. 2023. Available from:[ https://www.coursera.org/in/articles/big-data-analytics](https://www.coursera.org/in/articles/big-data-analytics)
1. Arena F, Pau G. An Overview of Big Data Analysis. Bull Electr Eng Inform. 2020;9(4):1646–53.
1. Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics Data Integration, Interpretation, and Its Application. Bioinformatics and Biology Insights. 2020;14:1–24.
1. Kaur P, Singh A, Chana I. Computational Techniques and Tools for Omics Data Analysis: State-of-the-Art, Challenges, and Future Directions. Arch Comput Methods Eng. 2021;28(7):4485–502.
1. Koppad S, Annappa B, Gkoutos GV, Acharjee A. Cloud Computing Enabled Big Multi-Omics Data Analytics. Bioinformatics and Biology Insights. 2021;15:1–16.
1. Arjmand B, Hamidpour SK, Tayanloo-Beik A, Goodarzi P, Aghayan HR, Adibi H, et al. Review of Multi-Omics Data Integration Approaches and Tools in Translational Research. Front Genet. 2022;13:824451.
1. Chen C, Chen H, Zhang Y, Thomas HR, Frank MH, He Y, Xia R. TBtools-II: A “One for All, All for One” Bioinformatics Platform for Biological Big-Data Mining. Mol Plant. 2023;16(10):1733–42.
1. What Is Big Data Analytics? Definition, Benefits, and More [Internet]. Coursera. 2023. Available from:[ https://www.coursera.org/in/articles/big-data-analytics](https://www.coursera.org/in/articles/big-data-analytics)
1. Leonelli S. Big Data in Biology: The Hope and Present. Hist Philos Life Sci. 2020;42(5):1–18.
1. Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics Data Integration, Interpretation, and Its Application. Bioinformatics Biol Insights. 2020;14:1–24.
1. Koppad S, Annappa B, Gkoutos GV, Acharjee A. Cloud Computing Enabled Big Multi-Omics Data Analytics. Bioinformatics Biol Insights. 2021;15:1–16.
1. Arjmand B, Hamidpour SK, Tayanloo-Beik A, Goodarzi P, Aghayan HR, Adibi H, et al. Review of Multi-Omics Data Integration Approaches and Tools in Translational Research. Front Genet. 2022;13:824451.
1. Feczko E, Fair DA. Methods and Challenges for Assessing Heterogeneity. Biol Psychiatry. 2020;88(1):9–17.
1. Kaur P, Singh A, Chana I. Computational Techniques and Tools for Omics Data Analysis: State-of-the-Art, Challenges, and Future Directions. Arch Comput Methods Eng. 2021;28(7):4485–502.
1. Wang Y, et al. Changing technologies of RNA sequencing and their applications in clinical oncology. Front Oncol. 2020;10:447.
1. Tzec-Interián J, et al. Bioinformatics perspectives on transcriptomics: A comprehensive review of bulk and single-cell RNA-seq. Quant Biol. 2025;2:1–29.
1. Conesa A, et al. A survey of best practices for RNA-seq data analysis. Genome Biol. 2016;17(1):13.
1. Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010.
1. Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: summarize analysis results for multiple tools and samples. Bioinformatics. 2016;32(19):3047–8.
1. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114–20.
1. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884–90.
1. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes. Genome Biol. 2013;14(4):R36.
1. Pertea M, et al. HISAT2: graph-based alignment of next generation sequencing data. Nat Methods. 2016;14:357–60.
1. Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.
1. Haas BJ, et al. De novo transcript sequence reconstruction using Trinity. Nat Protoc. 2013;8(8):1494–512.
1. Pertea G, et al. StringTie enables improved reconstruction of transcriptome. Nat Biotechnol. 2015;33(3):290–5.
1. Trapnell C, et al. Differential analysis with TopHat and Cufflinks. Nat Protoc. 2012;7(3):562–78.
1. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon: fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417–9.
1. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34(5):525–7.
1. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.
1. Robinson MD, McCarthy DJ, Smyth GK. edgeR: differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–40.
1. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
1. Lähnemann D, et al. Eleven grand challenges in single-cell data science. Genome Biol. 2020;21(1):31.
1. Svensson V, et al. Exponential scaling of scRNA-seq in the past decade. Nat Protoc. 2020;15(3):764–81.
1. Smith T, Heger A, Sudbery I. UMI-tools: modeling sequencing errors in Unique Molecular Identifiers. Genome Res. 2017;27(3):491–9.
1. Zheng GX, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049.
1. Kaminow B, Yunusov D, Dobin A. STARsolo: accurate, fast, and versatile mapping. Bioinformatics. 2021;37(3):1688–9.
1. Srivastava A, et al. Alevin efficiently estimates gene abundances. Genome Biol. 2019;20(1):65.
1. Melsted P, Booeshaghi AS, Liu L, Gao F, Lu L, Min KH, et al. Modular, efficient and constant-memory single-cell preprocessing. Nat Biotechnol. 2021;39(7):813–8.
1. Tian L, et al. scPipe: a flexible preprocessing pipeline for scRNA-seq. PLoS Comput Biol. 2018;14(8):e1006361.
1. Parekh S, Ziegenhain C, Vieth B, Enard W, Hellmann I. zUMIs: a fast and flexible pipeline for RNA sequencing data. GigaScience. 2018;7(6):1–9.
1. Hafemeister C, Satija R. Normalization and variance stabilization of scRNA-seq data using regularized negative binomial regression. Genome Biol. 2019;20:296.
1. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data. Nat Biotechnol. 2018;36(5):411–20.
1. Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 2018;19(1):15.
1. Finak G, et al. MAST: assessing transcriptional changes in scRNA-seq. Genome Biol. 2015;16(1):278.
1. Wang T, et al. DEsingle for detecting three types of differential expression. Bioinformatics. 2019;35(3):522–9.
1. Kharchenko PV, Silberstein L, Scadden DT. Bayesian approach to single-cell differential expression analysis. Nat Methods. 2014;11(7):740–2.
1. Trapnell C, et al. The dynamics and regulators of cell fate decisions. Nat Biotechnol. 2014;32(4):381–6.
1. Street K, Risso D, Fletcher RB, Das D, Ngai J, Yosef N, et al. Slingshot: pseudotime inference for single-cell transcriptomics. BMC Genom. 2018;19(1):477.
1. Wolf FA, et al. PAGA: graph abstraction for single-cell trajectory inference. Genome Biol. 2019;20(1):59.
1. Stark R, Grzelak M, Hadfield J. RNA sequencing: the teenage years. Nat Rev Genet. 2019;20(11):631–56.
1. Hong M, Tao S, Zhang L, et al. RNA sequencing: new technologies and applications in cancer research. J Hematol Oncol. 2020;13:166.
1. Jiang L, Chen H, Pinello L, Yuan GC. GiniClust: detecting rare cell types. Genome Biol. 2016;17:144.
1. Goncalves A, Tikhonov A, Brazma A, Kapushesky M. ArrayExpressHTS: A high-throughput pipeline for RNA-seq analysis. *Bioinformatics*. 2011;27(15):2271–2. doi:10.1093/bioinformatics/btr012.
1. Alonso A, Goñi J, Illana B, Rodríguez-Ezpeleta N. aRNApipe: A balanced, efficient and distributed pipeline for processing RNA-seq data in high performance computing environments. *Bioinformatics*. 2017;33(12):1727–9. doi:10.1093/bioinformatics/btx023.
1. Singh U, Oulhen N, Krischenowski O, Wessel GM. pyrpipe: A Python package for RNA-Seq workflows. *NAR Genomics and Bioinformatics*. 2021;3(1):lqab049. doi:10.1093/nargab/lqab049.
1. Hekselman I, Yeger-Lotem E. Mechanisms of tissue and cell-type specificity in heritable traits and diseases. Nature Reviews Genetics. 2020 Jan 8;21(3):137–50.
1. Molla Desta G, Birhanu AG. Advancements in single-cell RNA sequencing and spatial transcriptomics: transforming biomedical research. Acta Biochimica Polonica. 2025 Feb 5;72.
1. Sun G, Li Z, Rong D, Zhang H, Shi X, Yang W, et al. Single-cell RNA sequencing in cancer: Applications, advances, and emerging challenges. Molecular Therapy - Oncolytics. 2021 Jun;21:183–206.
1. Furkan Ozmen, Ozmen TY, Ors A, Mahnaz Janghorban, Rames MJ, Li X, et al. Single-cell RNA sequencing reveals different cellular states in malignant cells and the tumor microenvironment in primary and metastatic ER-positive breast cancer. npj Breast Cancer. 2025 Aug 26;11(1).
1. Gu Y, Zhang Z, Peter Ten Dijke. Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. Cellular & Molecular Immunology/Cellular & molecular immunology. 2023 Feb 24;20(4):318–40.
1. Sallee N, Artur Karasyov, Bellovin D, Liang R, Jacqueline, Palencia S, et al. Identification of a novel immune checkpoint regulator and potential therapeutic antibody target in oncology. Journal for ImmunoTherapy of Cancer. 2015 Nov 4;3(S2).
1. Ma YN, Xia Y, Karako K, Song P, Tang W, Hu X. Decoding Alzheimer’s Disease: Single-Cell Sequencing Uncovers Brain Cell Heterogeneity and Pathogenesis. Molecular Neurobiology. 2025 Apr 30;
1. Kuret T, Sodin-Šemrl S, Leskošek B, Ferk P. Single Cell RNA Sequencing in Autoimmune Inflammatory Rheumatic Diseases: Current Applications, Challenges and a Step Toward Precision Medicine. Frontiers in Medicine. 2022 Jan 18;8.
1. Yao Z, Feng Z, Zhang H, Zhang B. ScRNA-Seq reveals T cell immunity in COVID-19 patients and implications for immunotherapy. International Immunopharmacology. 2025 Apr 14;155:114663–3.
1. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57–63.
1. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet. 2011;12:87–98.
1. ` `Stark R, Grzelak M, Hadfield J. RNA sequencing: the teenage years. Nat Rev Genet. 2019;20(11):631–56.
1. Viegenhain C, Vieth B, Parekh S, et al. Comparative analysis of single-cell RNA sequencing methods. Mol Cell. 2017;65(4):631–44.
1. Hikkaduwa Withanage MH, Liang H, Zeng E. RNA-Seq experiment and data analysis. In: Estrogen Receptors: Methods and Protocols. Springer; 2022. p. 405–423.
1. Reuter JA, Spacek DV, Snyder MP. High-throughput sequencing technologies. Mol Cell. 2024;84(1):32–47.
1. Kharchenko PV, Silberstein L, Scadden DT. Bayesian approach to single-cell differential expression analysis. Nat Methods. 2014;11(7):740–42.
1. ` `Huang M, Wang J, Torre E, et al. SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods. 2018;15(7):539–42.
1. Tzec-Interián F, Singh R, Carvajal R. Bioinformatics perspectives on transcriptomics. Quant Biol. 2025;13(2):114–34.
1. ` `Lotfollahi M, Heydari H, Wolf FA, Theis FJ. scVI and scGPT: deep generative modeling for single-cell transcriptomics. Genome Biol. 2024;25(8):102–16.
1. Lähnemann D, Köster J, Szczurek E, et al. Eleven grand challenges in single-cell data science. Genome Biol. 2020;21(1):31.
1. Stuart T, Butler A, Hoffman P, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888–902.
1. Luecken MD, Theis FJ. Current best practices in single-cell RNA-seq analysis. Nat Rev Mol Cell Biol. 2024;25(3):180–96.
1. Srivastava D, Malik L, Smith T, et al. Cloud-based scalable pipelines for large-scale RNA-Seq. Nucleic Acids Res. 2023;51(5):2315–29.
1. McInnes L, Healy J, Melville J. UMAP: Uniform manifold approximation and projection. J Mach Learn Res. 2020;21:1–67.
1. Zappia L, Phipson B, Oshlack A. BiocMAP: scalable analysis of large single-cell RNA-Seq data. Bioinformatics. 2024;40(12):btad450.
1. Tasic B, Yao Z, Graybuck LT, et al. Shared and distinct transcriptomic cell types across neocortical areas. Nature. 2023;620:130–42.
1. Shabani M, Thorogood A, Knoppers BM. Data sharing in genomic research: ethical challenges revisited. Hum Genet. 2023;142(5):785–99.
1. National Institutes of Health. NIH Genomic Data Sharing Policy. Updated 2024. Available from: https://osp.od.nih.gov/scientific-sharing/genomic-data-sharing/
1. Juengst ET, McGowan ML. Ethical issues in personalized medicine. Annu Rev Genomics Hum Genet. 2023;24:293–310.
1. Mittelstadt BD, Floridi L. Ethics of biomedical data analytics. AI Soc. 2024;39(1):115–30.
1. Kiselev VY, Linnarsson S, Hemberg M. Towards a unified single-cell analysis ecosystem. Nat Biotechnol. 2025;43(1):9–18.
1. Wang Y, Mashock M, Tong Z, et al. Changing technologies of RNA sequencing and their applications in clinical oncology. Front Oncol. 2020;10:447.
1. ` `Luecken MD, Theis FJ. Current best practices in single-cell RNA-seq analysis. Nat Rev Mol Cell Biol. 2024;25(3):180–96.
1. Ståhl PL, Salmén F, Vickovic S, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353(6294):78–82.
1. Stickels RR, Murray E, Kumar P, et al. Highly sensitive spatial transcriptomics at near-cellular resolution with Slide-seqV2. Nat Biotechnol. 2021;39:313–19.
1. Xia C, Fan J, Emanuel G, et al. MERFISH: spatially resolved, multiplexed RNA profiling in single cells. Science. 2019;365(6450):379–82.
1. Zhang H, Liu X, Sun J, et al. Spatial transcriptomic analysis reveals immune microenvironment remodeling in breast cancer. Cell Rep Med. 2024;5(3):101122.
1. Tasic B, Yao Z, Graybuck LT, et al. Shared and distinct transcriptomic cell types across neocortical areas. Nature. 2023;620:130–42.
1. Asp M, Bergenstråhle J, Lundeberg J. Spatially resolved transcriptomes—next generation tools for tissue exploration. BioEssays. 2023;45(1):e2200283.
1. Palla G, Spitzer H, Klein M, et al. Squidpy: a scalable framework for spatial omics analysis. Nat Methods. 2022;19:1718–27.
1. Argelaguet R, Cuomo ASE, Stegle O, Marioni JC. Computational principles and challenges in single-cell data integration. Nat Biotechnol. 2021;39:1202–12.
1. ` `Ma S, Zhang B, LaFave LM, et al. Chromatin potential identified by shared single-cell profiling of RNA and chromatin. Cell. 2020;183(4):1103–16.
1. Stoeckius M, Hafemeister C, Stephenson W, et al. Simultaneous epitope and transcriptome measurement in single cells. Nat Methods. 2017;14:865–68.
1. Trefny MP, Seifert M, Wichert SP, et al. Single-cell metabolomics combined with transcriptomics reveals metabolic heterogeneity in immune cells. Cell Metab. 2023;35(6):1028–43.
1. Das A, Gupta R, Kumar S. Multi-omic integration reveals immune evasion mechanisms in lung cancer. Nat Commun. 2024;15(1):1421.
1. Lotfollahi M, Heydari H, Wolf FA, Theis FJ. scGPT: generative transformer models for single-cell omics. Genome Biol. 2024;25(8):102–16.
1. Gayoso A, Shor J, Faure L, et al. TotalVI: integrative analysis of RNA and protein data. Nat Methods. 2021;18(3):272–82.
1. Lähnemann D, Köster J, Szczurek E, et al. Eleven grand challenges in single-cell data science. Genome Biol. 2020;21(1):31.
1. Sun H, Guo X, Zhang Y, et al. Spatially resolved single-cell atlas of colorectal cancer progression. Cell Genom. 2025;5(2):101246.
1. Kim SY, Choi J, Cho Y, et al. Spatial transcriptomics reveals regeneration pathways in human cardiac tissue. Nat Commun. 2024;15(3):2104.
1. Zappia L, Phipson B, Oshlack A. BiocMAP: scalable analysis of large single-cell RNA-seq data. Bioinformatics. 2024;40(12):btad450.
1. NIH Bridge2AI Program. Building the foundation for trustworthy AI in biomedicine. Nat Med. 2023;29:1241–44.
1. Kiselev VY, Linnarsson S, Hemberg M. Towards a unified single-cell analysis ecosystem. Nat Biotechnol. 2025;43(1):9–18.

\
\

